Literature DB >> 10554529

[Effect of selenium on the side effect profile of adjuvant chemotherapy/radiotherapy in patients with breast carcinoma. Design for a clinical study].

K Schumacher.   

Abstract

Selenium is a very important component of the antioxidative protective mechanism which belong to every cell. By chemotherapy and radiotherapy a strong increase of free oxygen radicals is induced leading to a damage also of normal tissue. This phenomenon is registered as adverse drug reactions. Since, in addition, tumor patients frequently have low selenium blood levels the application of higher doses of selenium in connection with chemo- and radiotherapy will induce the toxicity of the treatment without lowering the efficiency. Within the presented prospective randomized placebo-controlled double-blind phase-III study we intend to answer the question whether the application of higher doses of sodium selenite will reduce the toxicity of chemotherapy and radiotherapy. Primary targets of the study are therefore the evaluation of toxicity according to CTC-criteria and of life quality.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10554529     DOI: 10.1007/bf03042191

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  27 in total

Review 1.  Evolving concepts in the systemic adjuvant treatment of breast cancer.

Authors:  G Bonadonna
Journal:  Cancer Res       Date:  1992-04-15       Impact factor: 12.701

Review 2.  The roles of calcium and phosphoinositides in the mechanisms of alpha 1-adrenergic and other agonists.

Authors:  J H Exton
Journal:  Rev Physiol Biochem Pharmacol       Date:  1988       Impact factor: 5.545

Review 3.  The inducible transcription factor NF-kappa B: structure-function relationship of its protein subunits.

Authors:  S Grimm; P A Baeuerle
Journal:  Biochem J       Date:  1993-03-01       Impact factor: 3.857

Review 4.  Clinical toxicities encountered with paclitaxel (Taxol).

Authors:  E K Rowinsky; E A Eisenhauer; V Chaudhry; S G Arbuck; R C Donehower
Journal:  Semin Oncol       Date:  1993-08       Impact factor: 4.929

Review 5.  The clinical pharmacology of paclitaxel (Taxol).

Authors:  E K Rowinsky; R C Donehower
Journal:  Semin Oncol       Date:  1993-08       Impact factor: 4.929

6.  Effects of selenium supplementation on immune parameters in gut failure patients on home parenteral nutrition.

Authors:  A Peretz; J Nève; J Duchateau; V Siderova; K Huygen; J P Famaey; Y A Carpentier
Journal:  Nutrition       Date:  1991 May-Jun       Impact factor: 4.008

Review 7.  Free radical-lipid interactions and their pathological consequences.

Authors:  C Rice-Evans; R Burdon
Journal:  Prog Lipid Res       Date:  1993       Impact factor: 16.195

8.  Selenium status of cancer patients in Greece.

Authors:  M S Bratakos; T P Vouterakos; P V Ioannou
Journal:  Sci Total Environ       Date:  1990-03       Impact factor: 7.963

9.  Intracellular glutathione levels regulate Fos/Jun induction and activation of glutathione S-transferase gene expression.

Authors:  S Bergelson; R Pinkus; V Daniel
Journal:  Cancer Res       Date:  1994-01-01       Impact factor: 12.701

Review 10.  [Paclitaxel (taxol)--a cytostatic drug with a new type of mechanism of action].

Authors:  B Schalhorn
Journal:  Med Klin (Munich)       Date:  1993-11
View more
  2 in total

1.  Cotherapy of Tiron and selenium against vanadium induced toxic effects in lactating rats.

Authors:  Sadhana Shrivastava; Deepmala Joshi; Monika Bhadauria; Sangeeta Shukla; Ramesh Mathur
Journal:  Iran J Reprod Med       Date:  2011

Review 2.  Antioxidants for the Treatment of Breast Cancer: Are We There Yet?

Authors:  Carmen Griñan-Lison; Jose L Blaya-Cánovas; Araceli López-Tejada; Marta Ávalos-Moreno; Alba Navarro-Ocón; Francisca E Cara; Adrián González-González; Jose A Lorente; Juan A Marchal; Sergio Granados-Principal
Journal:  Antioxidants (Basel)       Date:  2021-01-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.